Overview

• Lepodisiran, an experimental drug by Eli Lilly, reduced lipoprotein(a) (Lp(a)) levels by up to 94% in a Phase 2 trial involving 320 participants.
• The drug works by targeting messenger RNA to inhibit the production of apolipoprotein(a), a key component of Lp(a).
• High Lp(a) levels, a genetic risk factor for cardiovascular diseases, affect 1.4 billion people globally, including 64 million Americans.
• No serious adverse events were reported in the trial, and the drug demonstrated sustained efficacy over a year with infrequent dosing.
• Phase 3 trials are now enrolling participants to evaluate whether the drug’s Lp(a) reductions translate into fewer heart attacks and strokes.